Sorrento Therapeutics Inc. (SRNE) Financials Nov 14, 2014, 4:00 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Sorrento Therapeutics Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 0 682,568 529,184 583,774 460,148
Cost of Goods Sold (COGS) incl. D&A 2,755 23,413 2.57M - 1.29M
COGS excluding D&A 0 0 2.41M - 4,440
Depreciation & Amortization Expense 2,755 23,413 159,219 293,302 1.29M
Depreciation 2,755 23,413 159,219 293,302 486,337
Amortization of Intangibles 0 0 0 - 804,070
Gross Income (2,755) 659,155 (2.04M) - (834,699)
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 951,368 2.47M 1.2M 5.14M 14.85M
Research & Development 410,171 1.39M - 3.83M 9.02M
Other SG&A 541,197 1.08M 1.2M 1.31M 5.83M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 0 0 0 5.99M
EBIT after Unusual Expense 0 0 0 0 (5.99M)
Non Operating Income/Expense 0 0 0 0 0
Non-Operating Interest Income 11,857 3,786 5,951 7,300 9,615
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 0 0 0 0 253,194
Gross Interest Expense 0 0 0 0 253,194
Interest Capitalized 0 0 0 0 0
Pretax Income (942,266) (1.81M) (3.24M) (4.85M) (21.91M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (942,266) (1.81M) (3.24M) (4.85M) (21.91M)
Minority Interest Expense 0 0 0 0 0
Net Income (942,266) (1.81M) (3.24M) (4.85M) (21.91M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (942,266) (1.81M) (3.24M) (4.85M) (21.91M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (942,266) (1.81M) (3.24M) (4.85M) (21.91M)
EPS (Basic) (0.25) (0.25) (0.25) (0.50) (1.46)
Basic Shares Outstanding 6.08M 8.83M 9.92M 11.41M 15.05M
EPS (Diluted) (0.25) (0.25) (0.25) (0.50) (1.46)
Diluted Shares Outstanding 6.08M 8.83M 9.92M 11.41M 15.05M
EBITDA (951,368) (1.79M) (3.08M) (4.56M) (14.39M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Sorrento Therapeutics Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 0 682,568 529,184 583,774 460,148
Cost of Goods Sold (COGS) incl. D&A 2,755 23,413 2.57M - 1.29M
COGS excluding D&A 0 0 2.41M - 4,440
Depreciation & Amortization Expense 2,755 23,413 159,219 293,302 1.29M
Depreciation 2,755 23,413 159,219 293,302 486,337
Amortization of Intangibles 0 0 0 - 804,070
Gross Income (2,755) 659,155 (2.04M) - (834,699)
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 951,368 2.47M 1.2M 5.14M 14.85M
Research & Development 410,171 1.39M - 3.83M 9.02M
Other SG&A 541,197 1.08M 1.2M 1.31M 5.83M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 0 0 0 5.99M
EBIT after Unusual Expense 0 0 0 0 (5.99M)
Non Operating Income/Expense 0 0 0 0 0
Non-Operating Interest Income 11,857 3,786 5,951 7,300 9,615
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 0 0 0 0 253,194
Gross Interest Expense 0 0 0 0 253,194
Interest Capitalized 0 0 0 0 0
Pretax Income (942,266) (1.81M) (3.24M) (4.85M) (21.91M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (942,266) (1.81M) (3.24M) (4.85M) (21.91M)
Minority Interest Expense 0 0 0 0 0
Net Income (942,266) (1.81M) (3.24M) (4.85M) (21.91M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (942,266) (1.81M) (3.24M) (4.85M) (21.91M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (942,266) (1.81M) (3.24M) (4.85M) (21.91M)
EPS (Basic) (0.25) (0.25) (0.25) (0.50) (1.46)
Basic Shares Outstanding 6.08M 8.83M 9.92M 11.41M 15.05M
EPS (Diluted) (0.25) (0.25) (0.25) (0.50) (1.46)
Diluted Shares Outstanding 6.08M 8.83M 9.92M 11.41M 15.05M
EBITDA (951,368) (1.79M) (3.08M) (4.56M) (14.39M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
